Skip to content
Regional settings
Country
Please select the country whose regional site you wish to visit.
International
Australia
Germany
United Kingdom
Portugal
Poland
France
Spain
Italy
Switzerland
United States
Canada
Language
Please select the language of the regional site.
English
Language
Please select the language of the regional site.
English
Language
Please select the language of the regional site.
English
Deutsch
Language
Please select the language of the regional site.
English
Portuguese
Language
Please select the language of the regional site.
English
Polish
Language
Please select the language of the regional site.
English
French
Language
Please select the language of the regional site.
English
Spanish
Language
Please select the language of the regional site.
English
Italian
Language
Please select the language of the regional site.
English
Deutsch
French
Italian
Cancel
Our Company
Our team
Collaborative experts achieving remarkable results together.
Our Facility
Welcome to our state-of-the-art facility
Scientific advisory board
Expert guidance for scientific advancements
Career
Explore career opportunities with SOMAÍ
Investor relations
Strengthening connections, maximizing growth, fostering transparency
Our Approach
For Patients
Explore information on the therapeutic use of medical cannabis for those in need
For Healthcare Professionals
We partner with health professionals to educate and assist in the prescription of medicinal cannabis and therapy
For Partners
We provide an array of comprehensive solutions tailored to meet the needs of businesses operating in the cannabis industry
Products
News
Resources
Medical Cannabis Glossary
List of terms and their definitions.
Materials
Collection of articles and resources.
Conditions
Health states requiring diagnosis and treatment
Contacts
Home
SOMAÍ Pharmaceuticals
Scholar
Anne Schlag
Anne Schlag
Psychedelic humanities
Authors:
T Noorani, O Davis, A Dymock, N Langlitz, AK Schlag, E Dyck
Frontiers in Psychology 15, 1474064
Year:
2024
Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study
Authors:
MT Lynskey, H Thurgur, A Athanasiou-Fragkouli, AK Schlag, DJ Nutt
Archives of Suicide Research, 1-15
Year:
2024
Psychedelic Humanities
Authors:
E Dyck, T Noorani, N Langlitz, A Dymock, AK Schlag, O Davis
Frontiers Media SA
Year:
2024
OPEN ACCESS EDITED BY
Authors:
AK Schlag, K Greenway, L Fischman, E Jacobs
Psychedelic Humanities, 101
Year:
2024
Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21
Authors:
MT Lynskey, H Thurgur, A Athanasiou-Fragkouli, AK Schlag, DJ Nutt
Drugs & Aging, 1-10
Year:
2024
Using real world evidence to optimize care: the case of medical cannabis
Authors:
AK Schlag, DJ Nutt, M Lynskey
Expert Review of Pharmacoeconomics & Outcomes Research 24 (4), 463-465
Year:
2024
Feasibility of a cannabidiol‐dominant cannabis‐based medicinal product for the treatment of long COVID symptoms: A single‐arm open‐label feasibility trial
Authors:
H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson
British Journal of Clinical Pharmacology 90 (4), 1081-1093
Cited by:
2
Year:
2024
Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence
Authors:
MT Lynskey, A Athanasiou-Fragkouli, H Thurgur, AK Schlag, DJ Nutt
BJPsych Open 10 (2), e62
Year:
2024
Prescribed Medicinal Cannabis for the Treatment of Chronic Pain Comorbid with Depression: Real World Evidence from Project Twenty21
Authors:
A Athanasiou-Fragkouli, MT Lynskey, AK Schlag, DJ Nutt
Year:
2024
Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial.
Authors:
H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson
British Journal of Clinical Pharmacology
Year:
2023
Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model
Authors:
P McCrone, H Fisher, C Knight, R Harding, AK Schlag, DJ Nutt, JC Neill
Psychological Medicine 53 (16), 7619-7626
Cited by:
8
Year:
2023
Cannabis-based medicinal products (CBMPs) for the treatment of long COVID symptoms: current and potential applications
Authors:
H Thurgur, AK Schlag, E Iveson, A Hosseini, M Lynskey, DJ Nutt
Exploration of Medicine 4 (4), 487-503
Cited by:
2
Year:
2023
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Authors:
MJ Spriggs, A Murphy-Beiner, R Murphy, J Bornemann, H Thurgur, ...
Frontiers in Psychology 14, 1119115
Cited by:
7
Year:
2023
Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real-world evidence from project Twenty21
Authors:
MT Lynskey, AK Schlag, A Athanasiou-Fragkouli, D Badcock, DJ Nutt
Drug Science, Policy and Law 9, 20503245231167373
Cited by:
11
Year:
2023
Risks and adverse events associated with the use of psychedelics
Authors:
JC Neill, M Shahid, R Gittins, AK Schlag, FI Tarazi
Psychedelics as Psychiatric Medications, 113
Year:
2023
Medication sparing after medical cannabis initiation: A case study of a chronic pain patient in Project Twenty21
Authors:
P Sunderland, DJ Nutt, AK Schlag
Drug Science, Policy and Law 9, 20503245231157489
Cited by:
1
Year:
2023
Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research
Authors:
SL Bourke, AK Schlag, SE O'Sullivan, DJ Nutt, DP Finn
Pharmacology & therapeutics 240, 108216
Cited by:
32
Year:
2022
The value of real world evidence: the case of medical cannabis
Authors:
AK Schlag, RR Zafar, MT Lynskey, LD Phillips, DJ Nutt
Frontiers in Psychiatry 13, 1027159
Cited by:
24
Year:
2022
A comparative study of the harms of nitrous oxide and poppers using the MCDA approach
Authors:
PM Ferreira, AR Winstock, AK Schlag, B Brandner, G Henderson, I Miller, ...
Drug science, policy and law 8, 20503245221127301
Cited by:
3
Year:
2022
Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer
Authors:
R Zafar, D Sulak, J Brambila, D Nutt, A Schlag
Drug Science, Policy and Law 8, 20503245221114323
Cited by:
1
Year:
2022
A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products
Authors:
DJ Nutt, LD Phillips, MP Barnes, B Brander, HV Curran, A Fayaz, DP Finn, ...
Cannabis and cannabinoid research 7 (4), 482-500
Cited by:
41
Year:
2022
Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from project twenty 21
Authors:
AK Schlag, M Lynskey, A Fayaz, A Athanasiou-Fragkouli, B Brandner, ...
Frontiers in Pain Research 3, 891498
Cited by:
15
Year:
2022
Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21
Authors:
C Sakal, M Lynskey, AK Schlag, DJ Nutt
Psychopharmacology 239 (5), 1147-1155
Cited by:
39
Year:
2022
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Authors:
AK Schlag, J Aday, I Salam, JC Neill, DJ Nutt
Journal of Psychopharmacology 36 (3), 258-272
Cited by:
195
Year:
2022
Schedule 1 barriers to research in the UK: An in-depth qualitative analysis
Authors:
J Neill, A Howard, A Schlag, C Lennox
Drug Science, Policy and Law 7, 1-13
Year:
2022
Medical cannabis and epilepsy in the UK–A qualitative analysis of the carers’ perspective:“We're asking for quality of life for our children”
Authors:
AK Schlag, R Zafar, D Nutt
Drug Science, Policy and Law 7, 20503245211034930
Cited by:
9
Year:
2021
Cannabis based medicines and cannabis dependence: A critical review of issues and evidence
Authors:
AK Schlag, C Hindocha, R Zafar, DJ Nutt, HV Curran
Journal of Psychopharmacology 35 (7), 773-785
Cited by:
41
Year:
2021
Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics
Authors:
AK Schlag, SE O'Sullivan, RR Zafar, DJ Nutt
Neuropharmacology 191, 108586
Cited by:
59
Year:
2021
A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use
Authors:
S Rolles, AK Schlag, F Measham, L Phillips, D Nutt, D Bergsvik, ...
International Journal of Drug Policy 91, 103180
Cited by:
12
Year:
2021
Some contributions on how to formulate drug policies and provide evidence-based regulation
Authors:
S Rolles, DJ Nutt, AK Schlag
The American Journal of Bioethics 21 (4), 28-31
Cited by:
2
Year:
2021
Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients
Authors:
R Zafar, A Schlag, L Phillips, DJ Nutt
BMJ Paediatrics Open 5 (1)
Cited by:
9
Year:
2021
Ending the pain of children with severe epilepsy? an audit of the impact of medical cannabis in 10 patients
Authors:
RR Zafar, AK Schlag, DJ Nutt
Drug Science, Policy and Law 6, 2050324520974487
Cited by:
13
Year:
2020
Medical cannabis in the UK: from principle to practice
Authors:
AK Schlag, DS Baldwin, M Barnes, S Bazire, R Coathup, HV Curran, ...
Journal of Psychopharmacology 34 (9), 931-937
Cited by:
41
Year:
2020
So near yet so far: why won’t the UK prescribe medical cannabis?
Authors:
D Nutt, S Bazire, LD Phillips, AK Schlag
BMJ open 10 (9), e038687
Cited by:
49
Year:
2020
Percentages of problem drug use and their implications for policy making: A review of the literature
Authors:
AK Schlag
Drug Science, Policy and Law 6, 2050324520904540
Cited by:
55
Year:
2020
An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK?
Authors:
AK Schlag
Medical Cannabis and Cannabinoids 3 (1), 76-83
Cited by:
55
Year:
2020
A new approach to formulating and appraising drug policy: a multi-criterion decision analysis applied to alcohol and cannabis regulation
Authors:
O Rogeberg, D Bergsvik, LD Phillips, J Van Amsterdam, N Eastwood, ...
International Journal of Drug Policy 56, 144-152
Cited by:
58
Year:
2018
Looking back and going forward: what should the new European Commission do in order to promote evidence-based policy-making?
Authors:
R Lofstedt, AK Schlag
Journal of Risk Research 20 (11), 1359-1378
Cited by:
10
Year:
2017
Risk-risk tradeoffs: what should we do in Europe?
Authors:
R Lofstedt, A Schlag
Journal of Risk Research 20 (8), 963-983
Cited by:
33
Year:
2017
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
Authors:
I Singh, C Morgan, V Curran, D Nutt, A Schlag, R McShane
The Lancet Psychiatry 4 (5), 419-426
Cited by:
149
Year:
2017
Europeans and aquaculture: perceived differences between wild and farmed fish
Authors:
A Katrin Schlag, K Ystgaard
British Food Journal 115 (2), 209-222
Cited by:
104
Year:
2013
Aquaculture in Europe: media representations as a proxy for public opinion
Authors:
AK Schlag
International Journal of Fisheries and Aquaculture 3 (7), 158-165
Cited by:
50
Year:
2011
Aquaculture: an emerging issue for public concern
Authors:
AK Schlag
Journal of Risk Research 13 (7), 829-844
Cited by:
98
Year:
2010
Expert and lay representations of GM food: implications for risk communication
Authors:
AK Schlag
PQDT-UK & Ireland
Cited by:
4
Year:
2007
“Going back to our roots”. The role of nature in risk perception and risk communication of GM foods
Authors:
AK Schlag
Technik in einer fragilen Welt, 495-502
Year:
2005
Authors' response to letter ‘On the use of open‐label studies for the evaluation of cannabis‐based products for the treatment of long‐COVID’
Authors:
H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson
British Journal of Clinical Pharmacology
Year:
0
リアルワールドエビデンスの価値: 医療用大麻の場合
Authors:
AK Schlag, RR Zafar, MT Lynskey, A Athanasiou-Fragkouli, LD Phillips
Year:
0
Preprint not peer reviewed
Authors:
DJ Nutt, AK Schlag, JC Neill, V Chiruta
Year:
0